The SCOTS and SCOTS2 trials evaluated the safety and efficacy of autologous bone marrow-derived stem cells (BMSCs) in 34 eyes from patients with Stargardt Disease. BMSCs were administered via retrobulbar, subtenons, intravitreal, subretinal, and intravenous routes. After one year, 61.8% of eyes showed visual improvement, 23.5% remained stable, and 14.7%
